Pendulum on Fullscript

Pendulum: The Pioneers of Live Akkermansia

Clinically-studied, keystone strains designed to transform health through the gut microbiome.*

Loading navigation...

Reimagine the health of your patients by targeting the gut microbiome

Using cutting-edge technology and microbiome science, Pendulum was the first company in the US to market live Akkermansia muciniphila. Akkermansia supports the synthesis of health-promoting postbioitics and strengthens gut barrier integrity.*

Pendulum’s Akkermansia-containing formulations have been clinically studied and published in the British Medical Journal. Improving gut barrier function and maintaining healthy blood sugar levels with Pendulum’s strains is a foundational way to help your patients find optimal health by harnessing the power of the gut microbiome.*

Pendulum is now the #1 GI Doctor recommended Akkermansia brand product.**


Featured product

Join the 29,000+ practitioners recommending Pendulum products.^

How providers are using Pendulum’s GLP-1 Probiotic Pro in clinical practice

In survey of healthcare providers who use Pendulum’s GLP-1 Probiotic Pro:

  • 97% of healthcare providers recommend as a way to manage food cravings+
  • 78% Recommend as a strategy to help patients transition off of GLP-1 medications, specifically to help manage food cravings associated with this transition+
  • 64% Recommend as a first line approach before prescribing a GLP-1 medication+
  • 53% Recommend in combination with GLP-1 medications+
Survey

Fullscript and Pendulum provider survey with Akkermansia 500 Pro

98%

Will continue to recommend Akkermansia 500 Pro**

94%

Would recommend Akkermansia 500 Pro to other health care providers**

Study

Glucose control clinical efficacy

Pendulum conducted a double-blind, placebo-controlled nutrition study that demonstrated:

  • Pendulum Glucose Control’s safety for its intended use
  • Glucose control has a significant statistical and clinical impact on A1c and post-meal blood sugar spikes3
  • -0.6 A1c reduction
  • -32.5% post prandial glucose spike reduction

Fullscript accounts are $0/month — for everyone

Get your practice and patients up and running quickly at no cost.

References

*These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease.

**Based on a IQVIA survey of gastroenterologists, 2025

^Based on sales data, 2022-2025

+Based on a survey conducted internally in 2024 of 64 healthcare providers